Stocktoria
ImageneBio, Inc. IMA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-03-26
ImageneBio, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $800,000 | $3.5M | $9.2M | $15.6M | $31.0M |
| R&D expense | $28.5M | $32.1M | $59.7M | $64.3M | $47.1M |
| Operating income | -$48.5M | -$37.0M | -$75.4M | -$70.9M | -$34.1M |
| Income tax | -$350,000 | $13,000 | -$162,000 | $0 | $0 |
| Net income | -$45.3M | -$36.6M | -$68.2M | -$68.8M | -$34.1M |
| EPS (diluted) | $-9.64 | $-22.10 | $-1.63 | $-1.90 | $-1.22 |
| Operating cash flow | -$47.8M | -$21.3M | -$79.7M | -$74.1M | -$60.3M |
| Free cash flow | — | — | -$80.2M | -$75.5M | -$62.0M |
| Cash & equivalents | $94.5M | $12.1M | $119.9M | $59.9M | $232.2M |
| Total assets | $153.0M | $15.9M | $192.1M | $172.3M | $247.9M |
| Total liabilities | $19.8M | $17.4M | $22.3M | $25.3M | $40.0M |
| Shareholders' equity | $133.1M | -$160.6M | -$126.1M | $147.0M | $207.9M |
Source: SEC EDGAR filings · CIK 0001835579 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.